People living with PPMS in Australia have something to cheer about. #NewsSpeak #MSBlog
I just received an email from a pwMS about the good news down-under (see press release below). Let's hope the EMA & NICE have provide similar cheer for people living with PPMS in Europe and England, respectively. I wonder if other HTAs accepting the results of the ocrelizumab in PPMS trial (ORATORIO) and licensing ocrelizumab for PPMS, puts pressure on the EMA? I suspect not. To help, please have your say and complete the survey below. Thank you.
CoI: multiple
Labels: #NewsSpeak, Australia, ocrelizumab, primary progressive, Roche